Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Catches Rising Tide Of Antisense Neuroscience R&D

Executive Summary

Huntington's disease is one of several genetically defined neurological diseases that are being targeted in a multibillion-dollar collaboration forged between the US's Wave Life Sciences and Japan's Takeda, that could include co-commercialization by the biotech in the US.

Advertisement

Related Content

Finance Watch: Gossamer Works Around The Shutdown To Price Its $230m IPO
Start-Up Quarterly Statistics: Financings Finally Rise In Q1, But Deals Stagnate
Biopharma Quarterly Dealmaking Statistics, Q1 2018
Deal Watch: Fresenius Buyout Of Akorn Potentially Threatened By Data Integrity Issues
What Takeda's Failed TOMMORROW Trial Means For Early Alzheimer's Today
Deal Watch: As J.P. Morgan Waits For New Deals, Sanofi Takes Care Of Old Business
Biogen's Neuroscience Strategy Includes De-Risking The Pipeline

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100438

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel